➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Express Scripts
Mallinckrodt
AstraZeneca
Dow

Last Updated: January 24, 2021

DrugPatentWatch Database Preview

Celgene Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Celgene

Drugs and US Patents for Celgene

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Celgene POMALYST pomalidomide CAPSULE;ORAL 204026-002 Feb 8, 2013 AB RX Yes No 8,735,428*PED   Start Trial Y   Start Trial
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-005 Dec 21, 2011 RX Yes No 8,648,095   Start Trial   Start Trial
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-001 Dec 27, 2005 RX Yes No 9,393,238   Start Trial   Start Trial
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-001 Jul 16, 1998 RX Yes No 6,561,977   Start Trial   Start Trial
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-004 Jun 29, 2006 RX Yes Yes 6,755,784   Start Trial   Start Trial
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-004 Jun 29, 2006 RX Yes Yes   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Celgene

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-004 Jan 10, 2007 7,435,745   Start Trial
Celgene POMALYST pomalidomide CAPSULE;ORAL 204026-004 Feb 8, 2013 8,158,653   Start Trial
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-002 Dec 27, 2005 6,555,554   Start Trial
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-003 Jan 17, 2003 6,315,720   Start Trial
Celgene THALOMID thalidomide CAPSULE;ORAL 020785-004 Jan 10, 2007 7,723,361   Start Trial
Celgene REVLIMID lenalidomide CAPSULE;ORAL 021880-003 Jun 29, 2006 8,315,886   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for CELGENE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 1 mg, 2 mg, 3 mg and 4 mg ➤ Subscribe 2017-02-08
➤ Subscribe Capsules 5 mg, 10 mg and 15 mg ➤ Subscribe 2010-08-30
➤ Subscribe Capsules 50 mg and 100 mg ➤ Subscribe 2006-12-18
➤ Subscribe Capsules 150 mg ➤ Subscribe 2014-02-03
➤ Subscribe Capsules 25 mg ➤ Subscribe 2010-07-12
➤ Subscribe Capsules 2.5 mg and 20 mg ➤ Subscribe 2016-07-12
➤ Subscribe Capsules 200 mg ➤ Subscribe 2006-09-25
➤ Subscribe Injection 10 mg/vial ➤ Subscribe 2013-11-05

Supplementary Protection Certificates for Celgene Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2291080 2020C/539 Belgium   Start Trial PRODUCT NAME: OZANIMOD OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE CHLORHYDRATE D'OZANIMOD; AUTHORISATION NUMBER AND DATE: EU/1/20/1442 20200525
0688211 08C0036 France   Start Trial PRODUCT NAME: THALIDOMIDE; REGISTRATION NO/DATE: EU/1/08/443/001 20080416
2291080 LUC00177 Luxembourg   Start Trial PRODUCT NAME: OZANIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR OZANIMOD HYDROCHLORIDE; AUTHORISATION NUMBER AND DATE: EU/1/20/1442 20200525
2105135 1590004-6 Sweden   Start Trial PRODUCT NAME: POMALIDOMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS, SOLVATES, HYDRATES OR STEREOISOMERS THEREOF; REG. NO/DATE: EU/1/13/850 20130808
0688211 C300358 Netherlands   Start Trial PRODUCT NAME: THALIDOMIDE; REGISTRATION NO/DATE: EU/1/08/443/001 20080416
2105135 00140 Estonia   Start Trial
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Baxter
Mallinckrodt
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.